Gemcitabine/carboplatin in advanced non-small cell lung cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F02%3A00003693" target="_blank" >RIV/00216208:11120/02:00003693 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S0169-5002(02)00355-0" target="_blank" >http://dx.doi.org/10.1016/S0169-5002(02)00355-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0169-5002(02)00355-0" target="_blank" >10.1016/S0169-5002(02)00355-0</a>

Result language
angličtina
Original language name
Gemcitabine/carboplatin in advanced non-small cell lung cancer
Original language description
Gemcitabine/cisplatin is among the most widely used regimens in Europe for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologic toxicity and difficulty of use in outpatients. Carboplatin constitutes a reasonable alternative to cisplatin in this combination, since it shows synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematologic toxicity profile. Studies of gemcitabine/cisplatin on a 28-day schedule (gemcitabine on days 1, 8, 15 and carboplatin on day 1) generally indicate excessive thrombocytopenia. Use of a 21-day schedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity and comparable efficacy. Results of one randomized phase II study suggest reduced toxicity and reduced objective response rate with gemcitabine/carboplatin versus gemcitabine/cisplatin. We are currently conducting a phase III comparison of
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2002
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)